Cubist Systematic Strategies LLC Lowers Stake in ABIVAX Société Anonyme (NASDAQ:ABVX)

Cubist Systematic Strategies LLC lowered its position in shares of ABIVAX Société Anonyme (NASDAQ:ABVX) by 54.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,557 shares of the company’s stock after selling 8,896 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in ABIVAX Société Anonyme were worth $55,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. R Squared Ltd purchased a new position in ABIVAX Société Anonyme during the fourth quarter valued at approximately $36,000. Bank of America Corp DE lifted its holdings in ABIVAX Société Anonyme by 56.1% during the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after purchasing an additional 1,990 shares in the last quarter. Ameriprise Financial Inc. purchased a new position in ABIVAX Société Anonyme during the fourth quarter valued at approximately $85,000. Guggenheim Capital LLC purchased a new position in ABIVAX Société Anonyme during the fourth quarter valued at approximately $92,000. Finally, BNP Paribas Financial Markets lifted its holdings in ABIVAX Société Anonyme by 47.5% during the fourth quarter. BNP Paribas Financial Markets now owns 19,244 shares of the company’s stock valued at $141,000 after purchasing an additional 6,200 shares in the last quarter. Hedge funds and other institutional investors own 47.91% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on ABVX shares. Morgan Stanley reiterated an “equal weight” rating and set a $12.00 price objective on shares of ABIVAX Société Anonyme in a research report on Thursday, March 20th. JMP Securities reiterated a “market outperform” rating and set a $33.00 price objective on shares of ABIVAX Société Anonyme in a research report on Wednesday, April 30th. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, ABIVAX Société Anonyme presently has a consensus rating of “Buy” and an average target price of $34.00.

ABIVAX Société Anonyme Stock Performance

Shares of ABVX opened at $5.88 on Tuesday. The company’s fifty day moving average is $6.39 and its 200 day moving average is $7.20. ABIVAX Société Anonyme has a fifty-two week low of $4.77 and a fifty-two week high of $14.72.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.